Loading...
XNASATRC
Market cap1.53bUSD
Jan 10, Last price  
31.41USD
1D
-6.68%
1Q
12.82%
Jan 2017
60.50%
IPO
121.20%
Name

AtriCure Inc

Chart & Performance

D1W1MN
XNAS:ATRC chart
P/E
P/S
3.84
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
6.32%
Rev. gr., 5y
14.64%
Revenues
399m
+20.84%
19,157,03230,956,98738,243,24348,309,06355,257,02354,533,55859,006,18864,402,40970,247,00081,889,000107,454,000129,755,000155,109,000174,716,000201,630,000230,807,000206,531,000274,329,000330,379,000399,245,000
Net income
-30m
L-34.49%
-9,451,868-12,682,964-13,717,275-11,253,066-10,167,252-16,494,988-3,791,623-5,455,503-7,534,000-11,462,000-16,211,000-27,212,000-33,338,000-26,892,000-21,137,000-35,194,000-48,155,00050,199,000-46,466,000-30,438,000
CFO
4m
P
-3,800,071-7,615,909-12,465,730-8,115,628-5,709,940419,948-33,434-1,986,426-1,936,000-5,222,000-21,600,000-7,842,000-15,119,000-8,944,000-4,171,000-15,811,000-19,869,000-13,780,000-22,141,0004,484,000
Earnings
Feb 13, 2025

Profile

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
IPO date
Aug 05, 2005
Employees
1,050
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
399,245
20.84%
330,379
20.43%
Cost of revenue
172,790
141,776
Unusual Expense (Income)
NOPBT
226,455
188,603
NOPBT Margin
56.72%
57.09%
Operating Taxes
591
268
Tax Rate
0.26%
0.14%
NOPAT
225,864
188,335
Net income
(30,438)
-34.49%
(46,466)
-192.56%
Dividends
Dividend yield
Proceeds from repurchase of equity
(6,557)
(6,160)
BB yield
0.40%
0.30%
Debt
Debt current
2,533
5,472
Long-term debt
83,329
81,318
Deferred revenue
Other long-term liabilities
1,234
1,226
Net debt
(51,423)
(85,832)
Cash flow
Cash from operating activities
4,484
(22,141)
CAPEX
(11,998)
(16,881)
Cash from investing activities
21,817
44,006
Cash from financing activities
(32)
(7,059)
FCF
205,981
163,001
Balance
Cash
137,285
121,113
Long term investments
51,509
Excess cash
117,323
156,103
Stockholders' equity
(358,002)
(330,668)
Invested Capital
899,898
863,196
ROIC
25.62%
22.11%
ROCE
41.79%
35.42%
EV
Common stock shares outstanding
46,309
45,740
Price
35.69
-19.58%
44.38
-36.17%
Market cap
1,652,768
-18.58%
2,029,941
-36.59%
EV
1,601,345
1,944,109
EBITDA
241,268
200,313
EV/EBITDA
6.64
9.71
Interest
6,925
4,986
Interest/NOPBT
3.06%
2.64%